XENOTHERA is a clinical stage biotech company developing First-In-Class drugs mainly in oncology and hematology.

Their disruptive immunotherapy, based on a patented platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb), addresses major unmet medical needs, especially in solid and liquid tumors. Accelerated development is made possible due to scaled-up commercial grade industry, regulatory and clinical expertise, and in-house bioproduction facility.

XENOTHERA develops two main assets: LIS1, in Peripheral T-cell lymphoma (First Patient expected Q2 2024) and in Solid Organ Transplantation (confirmatory pivotal trial in preparation) and XON7, a pan-cancer GH-pAb targeting solid tumors, currently in Phase I/II.

–  Therapeutic areas: Oncology, Acute Graft rejection

–  Based in: Nantes (FRANCE)

–  Employees: 11 – 50

–  Created in: 2014